Pharmaceuticals
HJB and Mabspace Biosciences' Development and Manufacturing Agreement for Novel Humanized Claudin18.2 Monoclonal Antibody Accomplished FDA and NMPA IND Clearance
HANGZHOU, China, May 8, 2020 /PRNewswire/ -- HJB, a biologics CDMO committed to quality, reliability and speed for each and every CMCpackage delivered to its partners, today announces that its partner Mabspace Biosciences has received Investigational New Drug (IND) clearance from both the U.S. Fo...
2020-05-08 23:00
1942
Bridge Biotherapeutics Announces the IND Clearance of BBT-176, an EGFR TKI for NSCLC, in South Korea
* Following the US FDA's IND clearance, South Korea's MFDS cleared the IND application of BBT-176, submitted inDecember 2019 * BBT-176 will be the company's first drug candidate to launch clinical studies inSouth Korea * In the second half of this year, the company is expected to initiate a ...
2020-05-08 07:30
1681
Scientific Evidence Shows Everyday Hygiene Is Essential to Help Prevent the Spread of Infections, Reveals New Paper From The Global Hygiene Council
LONDON, May 8, 2020 /PRNewswire/ -- According to a new Position Paper published
in theAmerican Journal of Infection Control
2020-05-08 07:01
3770
DERMALOG Fever Detection at UKE Hamburg
HAMBURG, Germany, May 7, 2020 /PRNewswire/ -- Covid-19 currently shows how important it is to prevent the spread of infection as far as possible. Hospitals are facing a serious challenge, as staff and patients are at increased risk of infection. Fever screenings are increasingly being carried ...
2020-05-07 19:57
2928
Lipidor Presents Updated Project Plan - Initiates Phase III study of AKP02 in-House
STOCKHOLM, May 7, 2020 /PRNewswire/ -- In light of the company's successful Phase III study of calcipotriol spray (AKP01) against mild to moderate plaque psoriasis and subsequent discussions with pharmaceutical companies, the Board of Lipidor submits an updated project plan together with prioriti...
2020-05-07 18:20
2037
Lianhua Qingwen Receives Product Listing Approval from Singapore HSA
SHIJIAZHUANG, China, May 7, 2020 /PRNewswire/ -- Yiling Pharmaceutical (002603.SZ) announced that it has obtained the product listing approval issued by the Health Sciences Authority (HSA) ofSingapore which grants Lianhua Qingwen Capsule the initial sale authorization in the country. The approval...
2020-05-07 15:14
63020
TWi Biotechnology Receives Canada Health Approval for AC-1101 Phase 1 CTA
TAIPEI, Taiwan, May 7, 2020 /PRNewswire/ -- TWi Biotechnology (TWiB) announced that they have received Clinical Trial Application (CTA) approval from the Health Canada to conduct a Phase 1 clinical trial with AC-1101 gel. AC-1101 is a topical JAK inhibitor for the potential treatment of patients ...
2020-05-07 14:06
3246
Sai Life Sciences Joins the Global 'COVID Moonshot' Project
HYDERABAD, India, May 7, 2020 /PRNewswire/ -- Sai Life Sciences, one of India's
fastest growingContract Development & Manufacturing Organizations (CDMOs)
2020-05-07 09:00
4036
Tyvyt® (Sintilimab Injection) Combined with Gemzar® (Gemcitabine for Injection) and Platinum Chemotherapy Met the Predefined Primary Endpoint in the Phase 3 ORIENT-12 Study as First-Line Therapy in Patients with Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
SUZHOU, China, May 6, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, autoimmune, metabolic and other major diseases, today jointly...
2020-05-07 07:30
10615
Yiling Pharmaceutical Releases Financial Report for Q1 2020, Covid-19 TCM Lianhua Qingwen Research and Achievements Drive Growth
SHIJIAZHUANG, China, May 6, 2020 /PRNewswire/ -- Yiling Pharmaceutical (002603.SZ) has released its financial report for the first quarter of 2020. In the March quarter, Yiling Pharmaceutical achieved a total operating revenue of CNY 2.334 billion (USD $329 million) with 50.56% growth year-on-year...
2020-05-06 17:52
10432
Venturis Therapeutics, Inc. Announces its Applications for Four New Patents Related to the Use of Therapeutic Angiogenesis in the Treatment of Illnesses Related to the COVID-19 Virus, as Well as Illnesses Related to Other Viruses
DALLAS, May 6, 2020 /PRNewswire/ -- Venturis Therapeutics, Inc. ("VT") today announced it has applied for four provisional patents related to the treatment and/or prevention of virally induced illnesses related to the COVID-19 virus, as well as other viruses. These new patent applications cite th...
2020-05-06 09:26
2698
AGC Biologics Partners with Faron Pharmaceuticals to Manufacture Cancer Treatment
AGC Biologics will manufacture novel precision cancer immunotherapy treatment Clevegen SEATTLE, May 5, 2020 /PRNewswire/ -- AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has been selected to commercially manufacture the treatment Clevegen f...
2020-05-05 20:30
2696
Antengene Announces Expansion of Partnership with Karyopharm in Asia Pacific Markets
SHANGHAI, May 5, 2020 /PRNewswire/ -- Antengene Corporation (Antengene) today announced a broadened partnership and territory expansion agreement with Karyopharm Therapeutics Inc. (NASDAQ: KPTI) (Karyopharm) for development and commercialization of four oral novel drugs and drug candidates to s...
2020-05-05 20:30
1996
Ajinomoto Bio-Pharma Services Announces Manufacturing Partnership with CytoDyn for Drug Product Used in COVID-19 Clinical Trials
SAN DIEGO, May 5, 2020 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce it has entered into a manufacturing services agreement with CytoDyn Inc., a late stage biotechno...
2020-05-05 20:05
2241
Tessa Therapeutics Announces New Executive Leadership
SINGAPORE, May 5, 2020 /PRNewswire/ -- Tessa Therapeutics (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments, today announced thatJeffrey H. Buchalter will assume the role of Chief Executive Officer, and Göran A. Ando will become Chairman of the Board, wi...
2020-05-05 00:00
2302
Ascentage Pharma's Core Drug Candidate HQP1351 Granted Orphan Drug Designation by the US FDA for the Treatment of Patients with Chronic Myeloid Leukemia
SUZHOU, China, and ROCKVILLE, Md., May 4, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Adm...
2020-05-04 18:30
2072
Yiling Pharmaceutical to Increase Productivity of Lianhua Qingwen
SHIJIAZHUANG, China, May 4, 2020 /PRNewswire/ -- Yiling Pharmaceutical (002603.SZ) announced to launch the productivity-improving project ofLianhua Qingwen, a traditional Chinese medicine (TCM) used mainly for the treatment of colds and viral influenza. The Company is set to produce 7.5 billion c...
2020-05-04 08:15
4532
Reminder: Deadline To File Claims In The Purdue Pharma L.P. Bankruptcy Is June 30, 2020
NEW YORK, May 2, 2020 /PRNewswire/ -- The following is being issued by Prime Clerk, the court-appointed claims and noticing agent. This is a reminder that Tuesday, June 30, 2020, at 5:00 p.m. (Prevailing Eastern Time) is the deadline or bar date for filing claims in the bankruptcy of Purdue Phar...
2020-05-02 01:19
3373
Trio Pharmaceuticals, Inc. and Ajinomoto Bio-Pharma Services Enter into a Development Collaboration for a Novel Antibody Therapeutic
SAN DIEGO and SAN FRANCISCO, April 30, 2020 /PRNewswire/ -- Trio Pharmaceuticals, Inc. ("TRIO"), a cancer therapeutics company developing novel dual action antibody drugs, TRIObody™, and novel dual action antibody drug conjugates, TRIObody Drug Conjugate™ (TDC™) and Ajinomoto Bio-Pharma Services ...
2020-04-30 20:05
2653
Data From Merck at ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care
- Not intended for US-, Canada- or UK-based media - ASCO Abstract # BAVENCIO® (avelumab): LBA1, 5061; Bintrafusp alfa (bifunctional fusion protein):9558; Tepotinib (MET kinase inhibitor): 9556, 9575. - Late-breaking presentation of Phase III JAVELIN Bladder 100 data for BAVENCIO® showing over...
2020-04-30 20:00
2873
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
6217
